Profile of Multisystem Inflammatory Syndrome in Children (MIS-C) in Infants in North India during the Second Wave of SARS-CoV-2 Pandemic
Abstract Background: Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only older children, adolescents, and adults but also infants, more so during the second wave of the global pandemic. Materials and Methods: All se...
Saved in:
Published in | Indian journal of medical specialities Vol. 15; no. 3; pp. 145 - 151 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
India
Wolters Kluwer - Medknow
01.07.2024
Medknow Publications and Media Pvt. Ltd Wolters Kluwer Medknow Publications |
Edition | 2 |
Subjects | |
Online Access | Get full text |
ISSN | 0976-2884 0976-2892 |
DOI | 10.4103/injms.injms_196_23 |
Cover
Abstract | Abstract
Background:
Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only older children, adolescents, and adults but also infants, more so during the second wave of the global pandemic.
Materials and Methods:
All sequentially admitted infants hospitalized during 6 months who fulfilled the World Health Organization criteria for MIS-C or American Heart Association 2017 criteria for Kawasaki disease (KD) (and positive coronavirus disease-2019 [COVID-19] serology) were included in the present study.
Results:
A total of 19 infants were studied. Thirteen (68.3%) had evidence of recent COVID-19 infection. The median age of presentation was 2 months (interquartile range 25-75th, 0.5-3). The most common presenting symptoms were fever (68.4%), gastrointestinal complaints (63.1%), and edema (36.8%). Other predominant signs were shock (78.9%), myocarditis (52.6%), and neurological complaints (26.3%). Incomplete KD was present in 21% of patients. Elevated C-reactive protein, ferritin, D-Dimer, N-terminal prohormone of brain natriuretic peptide, and reduced fibrinogen were markers of severe illness. All subjects received intravenous immunoglobulin (IVIG) (100%), 31.5% received a second dose of IVIG, and 63.1% received pulse intravenous methylprednisolone. A total of 5 (26.3%) died as a result of the disease process.
Conclusion:
The spectrum of MIS-C in infants can be varied and is different from older children. A high index of suspicion is therefore needed in infants who present with critical illness and do not respond appropriately to conventional antibiotics and supportive care. The addition of IVIG and corticosteroids to the treatment regimen leads to a favorable outcome. |
---|---|
AbstractList | Abstract
Background:
Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only older children, adolescents, and adults but also infants, more so during the second wave of the global pandemic.
Materials and Methods:
All sequentially admitted infants hospitalized during 6 months who fulfilled the World Health Organization criteria for MIS-C or American Heart Association 2017 criteria for Kawasaki disease (KD) (and positive coronavirus disease-2019 [COVID-19] serology) were included in the present study.
Results:
A total of 19 infants were studied. Thirteen (68.3%) had evidence of recent COVID-19 infection. The median age of presentation was 2 months (interquartile range 25-75th, 0.5-3). The most common presenting symptoms were fever (68.4%), gastrointestinal complaints (63.1%), and edema (36.8%). Other predominant signs were shock (78.9%), myocarditis (52.6%), and neurological complaints (26.3%). Incomplete KD was present in 21% of patients. Elevated C-reactive protein, ferritin, D-Dimer, N-terminal prohormone of brain natriuretic peptide, and reduced fibrinogen were markers of severe illness. All subjects received intravenous immunoglobulin (IVIG) (100%), 31.5% received a second dose of IVIG, and 63.1% received pulse intravenous methylprednisolone. A total of 5 (26.3%) died as a result of the disease process.
Conclusion:
The spectrum of MIS-C in infants can be varied and is different from older children. A high index of suspicion is therefore needed in infants who present with critical illness and do not respond appropriately to conventional antibiotics and supportive care. The addition of IVIG and corticosteroids to the treatment regimen leads to a favorable outcome. Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only older children, adolescents, and adults but also infants, more so during the second wave of the global pandemic. All sequentially admitted infants hospitalized during 6 months who fulfilled the World Health Organization criteria for MIS-C or American Heart Association 2017 criteria for Kawasaki disease (KD) (and positive coronavirus disease-2019 [COVID-19] serology) were included in the present study. A total of 19 infants were studied. Thirteen (68.3) had evidence of recent COVID-19 infection. The median age of presentation was 2 months (interquartile range 25-75[sup.th], 0.5-3). The most common presenting symptoms were fever (68.4), gastrointestinal complaints (63.1), and edema (36.8). Other predominant signs were shock (78.9), myocarditis (52.6), and neurological complaints (26.3). Incomplete KD was present in 21 of patients. Elevated C-reactive protein, ferritin, D-Dimer, N-terminal prohormone of brain natriuretic peptide, and reduced fibrinogen were markers of severe illness. All subjects received intravenous immunoglobulin (IVIG) (100), 31.5 received a second dose of IVIG, and 63.1 received pulse intravenous methylprednisolone. A total of 5 (26.3) died as a result of the disease process. The spectrum of MIS-C in infants can be varied and is different from older children. A high index of suspicion is therefore needed in infants who present with critical illness and do not respond appropriately to conventional antibiotics and supportive care. The addition of IVIG and corticosteroids to the treatment regimen leads to a favorable outcome. Background: Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only older children, adolescents, and adults but also infants, more so during the second wave of the global pandemic. Materials and Methods: All sequentially admitted infants hospitalized during 6 months who fulfilled the World Health Organization criteria for MIS-C or American Heart Association 2017 criteria for Kawasaki disease (KD) (and positive coronavirus disease-2019 [COVID-19] serology) were included in the present study. Results: A total of 19 infants were studied. Thirteen (68.3%) had evidence of recent COVID-19 infection. The median age of presentation was 2 months (interquartile range 25–75th, 0.5–3). The most common presenting symptoms were fever (68.4%), gastrointestinal complaints (63.1%), and edema (36.8%). Other predominant signs were shock (78.9%), myocarditis (52.6%), and neurological complaints (26.3%). Incomplete KD was present in 21% of patients. Elevated C-reactive protein, ferritin, D-Dimer, N-terminal prohormone of brain natriuretic peptide, and reduced fibrinogen were markers of severe illness. All subjects received intravenous immunoglobulin (IVIG) (100%), 31.5% received a second dose of IVIG, and 63.1% received pulse intravenous methylprednisolone. A total of 5 (26.3%) died as a result of the disease process. Conclusion: The spectrum of MIS-C in infants can be varied and is different from older children. A high index of suspicion is therefore needed in infants who present with critical illness and do not respond appropriately to conventional antibiotics and supportive care. The addition of IVIG and corticosteroids to the treatment regimen leads to a favorable outcome. Background: Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only older children, adolescents, and adults but also infants, more so during the second wave of the global pandemic. Materials and Methods: All sequentially admitted infants hospitalized during 6 months who fulfilled the World Health Organization criteria for MIS-C or American Heart Association 2017 criteria for Kawasaki disease (KD) (and positive coronavirus disease-2019 [COVID-19] serology) were included in the present study. Results: A total of 19 infants were studied. Thirteen (68.3) had evidence of recent COVID-19 infection. The median age of presentation was 2 months (interquartile range 25-75[sup.th], 0.5-3). The most common presenting symptoms were fever (68.4), gastrointestinal complaints (63.1), and edema (36.8). Other predominant signs were shock (78.9), myocarditis (52.6), and neurological complaints (26.3). Incomplete KD was present in 21 of patients. Elevated C-reactive protein, ferritin, D-Dimer, N-terminal prohormone of brain natriuretic peptide, and reduced fibrinogen were markers of severe illness. All subjects received intravenous immunoglobulin (IVIG) (100), 31.5 received a second dose of IVIG, and 63.1 received pulse intravenous methylprednisolone. A total of 5 (26.3) died as a result of the disease process. Conclusion: The spectrum of MIS-C in infants can be varied and is different from older children. A high index of suspicion is therefore needed in infants who present with critical illness and do not respond appropriately to conventional antibiotics and supportive care. The addition of IVIG and corticosteroids to the treatment regimen leads to a favorable outcome. Keywords: Immunomodulation, intravenous immunoglobulin, Kawasaki disease, multisystem inflammatory syndrome in children |
Audience | Academic |
Author | Kumar, Ashna Mahto, Deonath Sehgal, Suchitra Basu, Srikanta Maheshwari, Anu Mahajan, Akanksha |
Author_xml | – sequence: 1 givenname: Ashna surname: Kumar fullname: Kumar, Ashna – sequence: 2 givenname: Anu surname: Maheshwari fullname: Maheshwari, Anu email: dranugulati@gmail.com – sequence: 3 givenname: Akanksha surname: Mahajan fullname: Mahajan, Akanksha – sequence: 4 givenname: Deonath surname: Mahto fullname: Mahto, Deonath – sequence: 5 givenname: Suchitra surname: Sehgal fullname: Sehgal, Suchitra – sequence: 6 givenname: Srikanta surname: Basu fullname: Basu, Srikanta |
BookMark | eNp9Ut1u0zAYjdCQGGMvwJUlbuAiJY4dO76sKgaVNjZRfi4tx_7cuktsZKdUfQMeG7cZE0gIW7I_HZ1z_HO-58WZDx6K4iWuZhRX5K3z2yHNTqvEgsmaPCnOK8FZWbeiPnusW_qsuExpW-VBhGCkOi9-3sVgXQ8oWHSz60eXDmmEAS297dUwqDHEA1odvIlhAOQ8WmxcbyJ49PpmuSoXb45YJis_pmP5McRxkwHjFDK76PwajRtAK9DBG_RN_TidtJp_ytrwtazRnfIGBqdfFE-t6hNcPuwXxZerd58XH8rr2_fLxfy61ITzVLLGCoyJwKTVYCjFrKKmxbrhFdE10Qa0MqQxDalBgWgsq2kLlDLccNMaQi6K5eRrgtrK79ENKh5kUE6egBDXUsXR6R5kxetOddACMEs7EF1rOdOaYqO45Z3JXq8mr7XKdOdtGKPSg0tazlssGiaY4Jk1-wcrz9O7c5TH__9bUE8CHUNKEezjNXElj4nLKes_E8-i20m0D_0IMd33uz1EOYC592H_H6XEtJEPXSCDlb-7gPwCml6_ww |
Cites_doi | 10.1001/jamapediatrics.2021.0038 10.1016/S0140-6736(20)31103-X 10.1056/NEJMoa2021756 10.1002/art.39332 10.1002/jmv.26951 10.1161/CIR.0000000000000484 10.1001/jama.2021.2091 10.1111/1756-185X.12854 10.3345/cep.2021.00913 10.5114/reum.2021.102871 10.3389/fped.2020.593455 10.1097/INF.0000000000003149 10.15585/mmwr.mm6932e2 10.1111/jpc.15675 10.1001/jamapediatrics.2021.0630 |
ContentType | Journal Article |
Copyright | Copyright: © 2024 Indian Journal of Medical Specialities COPYRIGHT 2024 Medknow Publications and Media Pvt. Ltd. |
Copyright_xml | – notice: Copyright: © 2024 Indian Journal of Medical Specialities – notice: COPYRIGHT 2024 Medknow Publications and Media Pvt. Ltd. |
DBID | AAYXX CITATION DOA |
DOI | 10.4103/injms.injms_196_23 |
DatabaseName | CrossRef DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 0976-2892 |
Edition | 2 |
EndPage | 151 |
ExternalDocumentID | oai_doaj_org_article_072babe8ee6f4be9b8f76cc41da7f7bd A819569697 10_4103_injms_injms_196_23 IMSP-15-145 |
GeographicLocations | United States India |
GeographicLocations_xml | – name: India – name: United States |
GroupedDBID | 0R~ 4.4 457 53G AALRI AAWTL AAXUO ACGFS ADBBV AEGXH AITUG ALMA_UNASSIGNED_HOLDINGS BAWUL BELOY C1A DIK EBS EIHBH EJD FDB GX1 H13 IAO IHR INH ITC O9- OK1 OVD RMW RNS ROL TEORI W3E AAYXX ADJBI CITATION GROUPED_DOAJ |
ID | FETCH-LOGICAL-c377s-65f91139138ced441604d81c5703c23cdecad35d532eae95f6248e446157d8d33 |
IEDL.DBID | DOA |
ISSN | 0976-2884 |
IngestDate | Mon Sep 08 19:52:56 EDT 2025 Tue Jun 17 22:02:10 EDT 2025 Tue Jun 10 21:01:10 EDT 2025 Tue Jul 01 01:41:05 EDT 2025 Wed May 28 23:14:48 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Kawasaki disease multisystem inflammatory syndrome in children Immunomodulation intravenous immunoglobulin |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c377s-65f91139138ced441604d81c5703c23cdecad35d532eae95f6248e446157d8d33 |
OpenAccessLink | https://doaj.org/article/072babe8ee6f4be9b8f76cc41da7f7bd |
PageCount | 7 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_072babe8ee6f4be9b8f76cc41da7f7bd gale_infotracmisc_A819569697 gale_infotracacademiconefile_A819569697 crossref_primary_10_4103_injms_injms_196_23 wolterskluwer_medknow_10_4103_injms_injms_196_23_145_Profile_of_Multisys |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-07-01 |
PublicationDateYYYYMMDD | 2024-07-01 |
PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | India |
PublicationPlace_xml | – name: India |
PublicationTitle | Indian journal of medical specialities |
PublicationYear | 2024 |
Publisher | Wolters Kluwer - Medknow Medknow Publications and Media Pvt. Ltd Wolters Kluwer Medknow Publications |
Publisher_xml | – name: Wolters Kluwer - Medknow – name: Medknow Publications and Media Pvt. Ltd – name: Wolters Kluwer Medknow Publications |
References | Zhao (R17-20240903) 2021; 93 Hobbs (R4-20240903) 2020; 8 Kok (R16-20240903) 2021; 64 Godfred-Cato (R9-20240903) 2020; 69 Godfred-Cato (R11-20240903) 2021; 40 Flannery (R21-20240903) 2021; 175 Dufort (R3-20240903) 2020; 383 Pawar (R20-20240903) 2021; 8 Belay (R19-20240903) 2021; 175 Feldstein (R18-20240903) 2021; 325 Verdoni (R2-20240903) 2020; 395 Maheshwari (R10-20240903) 2022; 58 McCrindle (R12-20240903) 2017; 135 Poniecka (R5-20240903) 2021; 59 Singh (R13-20240903) 2016; 19 Ravelli (R15-20240903) 2016; 68 |
References_xml | – volume: 175 start-page: 594 year: 2021 ident: R21-20240903 article-title: Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios publication-title: JAMA Pediatr doi: 10.1001/jamapediatrics.2021.0038 – volume: 395 start-page: 1771 year: 2020 ident: R2-20240903 article-title: An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic:an observational cohort study publication-title: Lancet doi: 10.1016/S0140-6736(20)31103-X – volume: 383 start-page: 347 year: 2020 ident: R3-20240903 article-title: Multisystem inflammatory syndrome in children in New York state publication-title: N Engl J Med doi: 10.1056/NEJMoa2021756 – volume: 68 start-page: 566 year: 2016 ident: R15-20240903 article-title: 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis:A European league against rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organization Collaborative Initiative publication-title: Arthritis Rheumatol doi: 10.1002/art.39332 – volume: 93 start-page: 4358 year: 2021 ident: R17-20240903 article-title: The inflammatory markers of multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19:A meta-analysis publication-title: J Med Virol doi: 10.1002/jmv.26951 – volume: 135 start-page: e927 year: 2017 ident: R12-20240903 article-title: Diagnosis, treatment, and long-term management of Kawasaki disease:A scientific statement for health professionals from the American Heart Association publication-title: Circulation doi: 10.1161/CIR.0000000000000484 – volume: 325 start-page: 1074 year: 2021 ident: R18-20240903 article-title: Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19 publication-title: JAMA doi: 10.1001/jama.2021.2091 – volume: 19 start-page: 924 year: 2016 ident: R13-20240903 article-title: Kawasaki disease in infants below 6 months:A clinical conundrum? publication-title: Int J Rheum Dis doi: 10.1111/1756-185X.12854 – volume: 8 start-page: 572 year: 2021 ident: R20-20240903 article-title: Neonatal Multisystem Inflammatory Syndrome (MIS-N) associated with prenatal maternal SARS-CoV-2:A case series publication-title: Children (Basel) – volume: 64 start-page: 599 year: 2021 ident: R16-20240903 article-title: Multisystem inflammatory syndrome in children and Kawasaki disease in infants:2 sides of the same coin? publication-title: Clin Exp Pediatr doi: 10.3345/cep.2021.00913 – volume: 59 start-page: 47 year: 2021 ident: R5-20240903 article-title: A fine line between macrophage activation syndrome and multisystem inflammatory syndrome in children –Literature review based on two case reports publication-title: Reumatologia doi: 10.5114/reum.2021.102871 – volume: 8 start-page: 593455 year: 2020 ident: R4-20240903 article-title: COVID-19 in children:A review and parallels to other hyperinflammatory syndromes publication-title: Front Pediatr doi: 10.3389/fped.2020.593455 – volume: 40 start-page: 601 year: 2021 ident: R11-20240903 article-title: Multisystem inflammatory syndrome in Infants <12 months of age, United States, May 2020-January 2021 publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0000000000003149 – volume: 69 start-page: 1074 year: 2020 ident: R9-20240903 article-title: COVID-19-Associated multisystem inflammatory syndrome in children –United States, March-July 2020 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm6932e2 – volume: 58 start-page: 136 year: 2022 ident: R10-20240903 article-title: Comparison of clinical and laboratory profile of survivors and non-survivors of SARS-CoV-2-related multisystem inflammatory syndrome of childhood in India:An observational study publication-title: J Paediatr Child Health doi: 10.1111/jpc.15675 – volume: 175 start-page: 837 year: 2021 ident: R19-20240903 article-title: Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic publication-title: JAMA Pediatr doi: 10.1001/jamapediatrics.2021.0630 |
SSID | ssj0000399630 |
Score | 2.2649667 |
Snippet | Abstract
Background:
Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only... Background: Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only older... Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only older children,... |
SourceID | doaj gale crossref wolterskluwer |
SourceType | Open Website Aggregation Database Index Database Publisher |
StartPage | 145 |
SubjectTerms | C-reactive protein Coronaviruses Ferritin Fibrin Health aspects immunomodulation Infants Infection intravenous immunoglobulin kawasaki disease multisystem inflammatory syndrome in children Natriuretic peptides Original Article |
SummonAdditionalLinks | – databaseName: Medknow Open Access Journals dbid: W3E link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagSAgJIZ7qloJ8QAKEDIlfcY7LimqLtKhiKfRm-SktaBPU3bZ_oT-7Yzstuwc4cYkSx3GcfDOescczg9ArUDqjjzYSYWtLeBCeKBskUSBKZGOM8DmYzuyLnB7zzyfiZAiTk3xhNuz3vK7Yh0X3c7l6n48aiEVTdhvdoQ1I5eQ9wv6sp1QgaWVOLVKBhCVUKV58ZP7SzJYcyuH6bwbl-xd9slSvfuWN6hvi5uAhejDoiXhcgH2EboXuMbo7GyzhT9DlUUm2jfuIsxNtCcmMD7sIGC-z7RzPh3AEeNHhyeC1jd_MDudk8jaVQeW0DSadZvsNFAC54OK6iEE1xPM0X_b4hznPb5qPv8Kz_XdC8VFafV4u3FN0fPDp22RKhqwKxLGmWREpIgxwrK2ZcsGDNiQr7lXtUiguR5nzwRnPhBeMBhNaESXlKgBytWi88ow9Qztd34VdhCtLTUxp8FqmODMxXUpnWmMsFyAGR-jd9T_Wv0vwDA2TjoSILlhsIjJCHxMMNzVT4OtcAPSgBz7SVUOtsUGFICO3obUqNtI5XnvTxMb6EXqdQNSJPdenxpnBywA6nEDR42Q3lK1soXP7WzWBrdzW7ekWGehlcU_8xwfANEroAX3dR32N_t7_a-o5ukdBqyr7hffRzvr0LLwArWhtX2Z2uAJXWA9W priority: 102 providerName: Wolters Kluwer Health |
Title | Profile of Multisystem Inflammatory Syndrome in Children (MIS-C) in Infants in North India during the Second Wave of SARS-CoV-2 Pandemic |
URI | https://doi.org/10.4103/injms.injms_196_23 https://doaj.org/article/072babe8ee6f4be9b8f76cc41da7f7bd |
Volume | 15 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA_ShyKI1C88rZIHQUVid_O12cfr0XIVTopnbd9CPuEqtyu9q_4L_bM7Sbbl7kVffAm72Syb5DfJzOxkZhB6B0Jn9NFGImxtCQ_CE2WDJApYiWyMET4H05l9ldMz_uVCXGyk-kpnwkp44DJxB1VDrbFBhSAjt6G1KjbSOV5708TG-rT7Vm21oUzlPRj4rsyJRirgt4QqxYvHDK8rdrDoLperz7nUQIGasi2ulIP332_Rj_70yW69-pmPrW8wn-M99HiQGvG49PYJehC6p2h3NtjFn6Gb05J6G_cRZ5faEqAZn3QREF9mSzqeD8EJ8KLDk8GHG3-YnczJ5GOqg8bpUEy6zNYcqADiwcWREYOgiOdJe_b43PzOX5qPv8G7_Q9C8Wn6F71cuOfo7Pjo-2RKhhwLxLGmWREpImx3rK2ZcsGDbCQr7lXtUmAuR5nzwRnPhBeMBhNaESXlKgCOtWi88oy9QDtd34WXCFeWmpiS4rVMcWZiupXOtMZYLoApjtCnuznWv0ooDQ0qSEJEFyw2ERmhwwTDfcsUBjtXAHHogTj0v4hjhN4nEHVarOsr48zgcwAdTqDocbIiyla20Ln9rZawyNzW4-kWGehlcVb8ywBAqRJ6QF_3Ud-h_-p_DOw1ekhBuirnhvfRzvrqOrwB6Wht3-aFAOU5O7oFCCoSxw |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Profile+of+Multisystem+Inflammatory+Syndrome+in+Children+in+Infants+in+North+India+during+the+Second+Wave+of+SARS-CoV-2+Pandemic&rft.jtitle=Indian+journal+of+medical+specialities&rft.au=Kumar%2C+Ashna&rft.au=Maheshwari%2C+Anu&rft.au=Mahajan%2C+Akanksha&rft.au=Mahto%2C+Deonath&rft.date=2024-07-01&rft.pub=Medknow+Publications+and+Media+Pvt.+Ltd&rft.issn=0976-2884&rft.volume=15&rft.issue=3&rft.spage=145&rft_id=info:doi/10.4103%2Finjms.injms_196_23&rft.externalDocID=A819569697 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0976-2884&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0976-2884&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0976-2884&client=summon |